

Publication Date: 27.01.2020 14:00

**EANS-Voting Rights: Marinomed Biotech AG / Publication of a participation notification according to art. 135 para. 2 Stock Exchange Act**

Notification of voting rights transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.

Overview

1. Issuer: Marinomed Biotech AG
2. Reason for the notification: Acquisition or disposal of voting rights
3. Person subject to notification obligation  
Acting in concert (Sec. 133 No. 7 BörseG 2018)

First name	Name/Surname	City	Country
Abdulgohsen	Al Sheikh		
Mohammed	Al Sheikh		
	Acropora Beteiligungs GmbH	Vienna	Austria

4. Name of shareholder(s):
5. Date on which the threshold was crossed or reached: 22.1.2020
6. Total positions:

	% of voting rights attached to shares (7.A)	% of voting rights through financial/other instruments (7.B.1 + 7.B.2)	Total of both in % (7.A + 7.B)	Total number of voting rights of issuer
Resulting situation on the date on which threshold was crossed / reached	16.59 %	0,00 %	16.59 %	1,469,772
Position of previous notification (if applicable)	23.27 %	0,00 %	23.27 %	

Details

7. Notified details of the resulting situation:

A: Voting rights attached to shares				
ISIN Code	Number of voting rights		% of voting rights	
	Direct (Sec 130 BörseG 2018)	Indirect (Sec 133 BörseG 2018)	Direct (Sec 130 BörseG 2018)	Indirect (Sec 133 BörseG 2018)

AT0000831706	243,860		16.59 %	
SUBTOTAL A		243,860		16.59%

B 1: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 1 BörseG 2018				
Type of instrument	Expiration Date	Exercise Period	Number of voting rights that may be acquired if the instrument is exercised	% of voting rights
		SUBTOTAL B.1		

B 2: Financial / Other Instruments pursuant to Sec. 131 para. 1 No. 2 BörseG 2018					
Type of instrument	Expiration Date	Exercise Period	Physical / Cash Settlement	Number of voting rights	% of voting rights
			SUBTOTAL B.2		

8. Information in relation to the person subject to the notification obligation:  
Full chain of controlled undertakings through which the voting rights and/or the financial/other instruments are effectively held starting with the ultimate controlling natural person or legal entity:

No.	Name	Directly controlled by No.	Shares held directly (%)	Financial/ other instruments held directly (%)	Total of both (%)
1	Abdulmohsen Al Sheikh				
2	Mohammed Al Sheikh				
3	Acropora Beteiligungs GmbH	1,2	16.59 %		16.59 %

9. In case of proxy voting

Date of general meeting: -

Voting rights after general meeting: - is equivalent to - voting rights.

10. Additional comments:

The disclosure obligation arose because the number of shares held dropped below the threshold due to the sale of 73,500 shares.

Further inquiry note:

Dr. Eva Prieschl-Grassauer  
Chief Scientific Officer, Marinomed  
Veterinärplatz 1, 1210 Vienna, Austria  
T +43 (0)1 250 77 4460  
E-Mail: [eva.prieschl@marinomed.com](mailto:eva.prieschl@marinomed.com)  
<http://www.marinomed.com>

Roland Mayrl  
Managing Partner, Metrum Communications  
Bauernmarkt 10/19, 1010 Vienna, Austria  
T +43 (0) 1 504 69 87 331  
E-Mail: [r.mayrl@metrum.at](mailto:r.mayrl@metrum.at)  
<http://www.metrum.at>

end of announcement

euro adhoc

-----

issuer: Marinomed Biotech AG  
Veterinärplatz 1  
A-1210 Wien  
phone: 0043250774460  
FAX: 0043250774493  
mail: [office@marinomed.com](mailto:office@marinomed.com)  
WWW: [www.marinomed.com](http://www.marinomed.com)  
ISIN: ATMARINOMED6, AT0000A1WD52  
indexes:  
stockmarkets: Wien  
language: English



Aussendung übermittelt durch euro adhoc  
The European Investor Relations Service